Latest & greatest articles for dementia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on dementia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on dementia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for dementia

1. Medical Cannabis for the Treatment of Dementia: A Review of Clinical Effectiveness and Guidelines

Medical Cannabis for the Treatment of Dementia: A Review of Clinical Effectiveness and Guidelines Medical Cannabis for the Treatment of Dementia: A Review of Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Medical Cannabis for the Treatment of Dementia: A Review of Clinical Effectiveness and Guidelines Medical Cannabis for the Treatment of Dementia: A Review of Clinical Effectiveness and Guidelines Last updated: July 17, 2019 Project Number: RC1152-000 Product (...) Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of medical cannabis for the treatment of dementia? What are the evidence-based guidelines associated with the use of medical cannabis for the treatment of dementia? Key Message Limited evidence from one systematic review3 and one uncontrolled before-and-after study10 suggested that medical cannabis may be effective for treating agitation, disinhibition, irritability

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

2. Electroconvulsive Therapy for the Treatment of the Behavioural and Psychological Symptoms of Dementia: A Review of Clinical Effectiveness and Guidelines

Electroconvulsive Therapy for the Treatment of the Behavioural and Psychological Symptoms of Dementia: A Review of Clinical Effectiveness and Guidelines Electroconvulsive Therapy for the Treatment of the Behavioural and Psychological Symptoms of Dementia: A Review of Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Electroconvulsive Therapy for the Treatment of the Behavioural and Psychological Symptoms of Dementia: A Review of Clinical Effectiveness and Guidelines (...) Electroconvulsive Therapy for the Treatment of the Behavioural and Psychological Symptoms of Dementia: A Review of Clinical Effectiveness and Guidelines Last updated: May 22, 2019 Project Number: RC1114-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of electroconvulsive therapy for the treatment of the behavioural and psychological symptoms of dementia in older adults? What is the safety

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

3. Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary

Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary | The Medical Journal of Australia mja-search search Use the for more specific terms. Title contains Body contains Date range from Date range to Article type Author's surname Volume First page doi: 10.5694/mja__.______ Search Reset  close Individual Login Purchase options Connect person_outline Login keyboard_arrow_down (...) Individual Login Purchase options menu search Advertisement close Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary Emily Reeve, Barbara Farrell, Wade Thompson, Nathan Herrmann, Ingrid Sketris, Parker J Magin, Lynn Chenoweth, Mary Gorman, Lyntara Quirke, Graeme Bethune and Sarah N Hilmer Med J Aust 2019; 210 (4): . || doi: 10.5694/mja2.50015 Published online: 4 March 2019 Topics Abstract Introduction: Cholinesterase inhibitors (ChEIs) and memantine are medications used

2019 MJA Clinical Guidelines

4. Decreasing the incidence of dementia through treatment of herpes virus with antiviral therapy

Decreasing the incidence of dementia through treatment of herpes virus with antiviral therapy ""Decreasing the incidence of dementia through treatment of herpes viru" by Stephen Webber and Evan Eisher < > > > > > Title Author Date of Graduation Summer 8-10-2019 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Dementia is the fifth leading cause of death worldwide with significant effects on healthcare costs and caregiver (...) demands. Therapy up to this point has only shown marginal benefit in delaying the disease. Focus on preventative treatment now is of upmost importance. The link between herpes virus infection and the development of dementia has been well researched, and is an area of focus that may result in preventative therapy. The aim of this study is to assess the efficacy of herpes antiviral treatment in the prevention of dementia. Methods: An exhaustive search of medical literature, including the databases

2019 Pacific University EBM Capstone Project

5. Weighted Blankets for Dementia Care in Long-Term Care: Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Weighted Blankets for Dementia Care in Long-Term Care: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Weighted Blankets for Dementia Care in Long-Term Care: Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Weighted Blankets for Dementia Care in Long-Term Care: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Weighted Blankets for Dementia Care in Long-Term Care: Clinical Effectiveness, Cost-Effectiveness, and Guidelines (...) Last updated: January 24, 2019 Project Number: RB1301-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of using weighted blankets for patients with dementia in long-term care? What is the cost-effectiveness of using weighted blankets for patients with dementia in long-term care? What are the evidence-based guidelines associated with the use of weighted blankets for patients with dementia in long

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

6. Dementia

Dementia Revised 2019 ACR Appropriateness Criteria ® 1 Dementia American College of Radiology ACR Appropriateness Criteria ® Dementia Variant 1: Cognitive decline. Suspected Alzheimer disease. Initial imaging. Procedure Appropriateness Category Relative Radiation Level MRI head without IV contrast Usually Appropriate O CT head without IV contrast Usually Appropriate ??? F-18 amyloid PET/CT brain May Be Appropriate ??? FDG-PET/CT brain May Be Appropriate ???? MRI head without and with IV (...) contrast Usually Not Appropriate O Tc-99m HMPAO SPECT/CT brain Usually Not Appropriate ???? MR spectroscopy head without IV contrast Usually Not Appropriate O MRI functional (fMRI) head without IV contrast Usually Not Appropriate O CT head with IV contrast Usually Not Appropriate ??? CT head without and with IV contrast Usually Not Appropriate ??? Variant 2: Suspected frontotemporal dementia. Initial imaging. Procedure Appropriateness Category Relative Radiation Level MRI head without IV contrast

2019 American College of Radiology

7. Non-Invasive Brain Stimulation Techniques for the Treatment of the Behavioural and Psychological Symptoms of Severe Dementia: Clinical Effectiveness

Non-Invasive Brain Stimulation Techniques for the Treatment of the Behavioural and Psychological Symptoms of Severe Dementia: Clinical Effectiveness Non-Invasive Brain Stimulation Techniques for the Treatment of the Behavioural and Psychological Symptoms of Severe Dementia: Clinical Effectiveness | CADTH.ca Find the information you need Non-Invasive Brain Stimulation Techniques for the Treatment of the Behavioural and Psychological Symptoms of Severe Dementia: Clinical Effectiveness Non (...) -Invasive Brain Stimulation Techniques for the Treatment of the Behavioural and Psychological Symptoms of Severe Dementia: Clinical Effectiveness Last updated: April 24, 2019 Project Number: RA1027-000 Product Line: Research Type: Devices and Systems Report Type: Reference List Result type: Report Question What is the clinical effectiveness of non-invasive brain stimulation techniques for the behavioural and psychological symptoms of dementia? Key Message Ten systematic reviews (seven with meta-analyses

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

8. Mini-Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a secondary care setting. (PubMed)

Mini-Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a secondary care setting. The diagnosis of Alzheimer's disease dementia and other dementias relies on clinical assessment. There is a high prevalence of cognitive disorders, including undiagnosed dementia in secondary care settings. Short cognitive tests can be helpful in identifying those who require further specialist diagnostic assessment; however, there is a lack of consensus around the optimal tools (...) to use in clinical practice. The Mini-Cog is a short cognitive test comprising three-item recall and a clock-drawing test that is used in secondary care settings.The primary objective was to determine the diagnostic accuracy of the Mini-Cog for detecting Alzheimer's disease dementia and other dementias in a secondary care setting. The secondary objectives were to investigate the heterogeneity of test accuracy in the included studies and potential sources of heterogeneity. These potential sources

2019 Cochrane

9. Dementia. (PubMed)

Dementia. Alzheimer disease (AD) and other dementia syndromes are becoming more common; an estimated 5.5 million adults aged 65 years or older are living with AD in the United States. It is important for primary care physicians to gain knowledge in this field because most community-dwelling older adults receive their care from them. This article discusses the latest findings in approaches to prevent cognitive decline as well as dementia screening, diagnosis, and treatment. Approaches to address (...) quality of life for persons with dementia and their caregivers are also discussed.

2019 Annals of Internal Medicine

10. Steps to better understanding resistant behaviours in hospitalised patients with dementia. (PubMed)

Steps to better understanding resistant behaviours in hospitalised patients with dementia. The studyFeatherstone K, Northcott A, Harden J, et al. Refusal and resistance to care by people living with dementia being cared for within acute hospital wards: an ethnographic study. Health Serv Deliv Res 2019;7.This study was funded by the National Institute for Health Research Health Services and Delivery Research Programme (project number 13/10/80).To read the full NIHR Signal, go to https (...) ://discover.dc.nihr.ac.uk/content/signal-000779/understanding-dementia-care-in-hospitals.Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

2019 BMJ

11. Association of Midlife to Late-Life Blood Pressure Patterns With Incident Dementia. (PubMed)

Association of Midlife to Late-Life Blood Pressure Patterns With Incident Dementia. The association between late-life blood pressure (BP) and cognition may depend on the presence and chronicity of past hypertension. Late-life declines in blood pressure following prolonged hypertension may be associated with poor cognitive outcomes.To examine the association of midlife to late-life BP patterns with subsequent dementia, mild cognitive impairment, and cognitive decline.The Atherosclerosis Risk (...) on December 31, 2017.Five groups based on longitudinal patterns of normotension, hypertension (>140/90 mm Hg), and hypotension (<90/60 mm Hg) at visits 1 to 5.Primary outcome was dementia onset after visit 5, based on Ascertain Dementia-8 informant questionnaires, Six-Item Screener telephone assessments, hospital discharge and death certificate codes, and the visit 6 neurocognitive evaluation. Secondary outcome was mild cognitive impairment at visit 6, based on the neurocognitive evaluation.Among 4761

2019 JAMA

12. Association of ideal cardiovascular health at age 50 with incidence of dementia: 25 year follow-up of Whitehall II cohort study. (PubMed)

Association of ideal cardiovascular health at age 50 with incidence of dementia: 25 year follow-up of Whitehall II cohort study. To examine the association between the Life Simple 7 cardiovascular health score at age 50 and incidence of dementia.Prospective cohort study.Civil service departments in London (Whitehall II study; study inception 1985-88).7899 participants with data on the cardiovascular health score at age 50.The cardiovascular health score included four behavioural (smoking, diet (...) , physical activity, body mass index) and three biological (fasting glucose, blood cholesterol, blood pressure) metrics, coded on a three point scale (0, 1, 2). The cardiovascular health score was the sum of seven metrics (score range 0-14) and was categorised into poor (scores 0-6), intermediate (7-11), and optimal (12-14) cardiovascular health.Incident dementia, identified through linkage to hospital, mental health services, and mortality registers until 2017.347 incident cases of dementia were

2019 BMJ

13. Association of Lifestyle and Genetic Risk With Incidence of Dementia. (PubMed)

Association of Lifestyle and Genetic Risk With Incidence of Dementia. Genetic factors increase risk of dementia, but the extent to which this can be offset by lifestyle factors is unknown.To investigate whether a healthy lifestyle is associated with lower risk of dementia regardless of genetic risk.A retrospective cohort study that included adults of European ancestry aged at least 60 years without cognitive impairment or dementia at baseline. Participants joined the UK Biobank study from 2006 (...) to 2010 and were followed up until 2016 or 2017.A polygenic risk score for dementia with low (lowest quintile), intermediate (quintiles 2 to 4), and high (highest quintile) risk categories and a weighted healthy lifestyle score, including no current smoking, regular physical activity, healthy diet, and moderate alcohol consumption, categorized into favorable, intermediate, and unfavorable lifestyles.Incident all-cause dementia, ascertained through hospital inpatient and death records.A total

2019 JAMA

14. Setting goals can help people with early stage dementia improve function. (PubMed)

Setting goals can help people with early stage dementia improve function. The studyClare L, Kudlicka A, Oyebode J R, et al. Goal-oriented cognitive rehabilitation for early-stage Alzheimer's and related dementias: the GREAT RCT. Health Technol Assess 2019;23:1-242.The trial was funded by the NIHR Health Technology Assessment Programme (project number11/15/04).To read the full NIHR Signal, go to: https://discover.dc.nihr.ac.uk/content/signal-000767/goal-setting-in-early-stage-dementia-can

2019 BMJ

15. Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia. (PubMed)

Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia. A National Institute on Aging and Alzheimer's Association workgroup proposed a research framework for Alzheimer disease in which biomarker classification of research participants is labeled AT(N) for amyloid, tau, and neurodegeneration biomarkers.To determine the associations between AT(N) biomarker profiles and memory decline in a population-based cohort (...) of individuals without dementia age 60 years or older, and to determine whether biomarkers provide incremental prognostic value beyond more readily available clinical and genetic information.Population-based cohort study of cognitive aging in Olmsted County, Minnesota, that included 480 nondemented Mayo Clinic Study of Aging participants who had a clinical evaluation and amyloid positron emission tomography (PET) (A), tau PET (T), and magnetic resonance imaging (MRI) cortical thickness (N) measures between

2019 JAMA

16. ACR–ASNR Practice Parameter for Brain PET/CT Imaging Dementia Res. 17 – 2015 - 2019

ACR–ASNR Practice Parameter for Brain PET/CT Imaging Dementia Res. 17 – 2015 - 2019 PRACTICE PARAMETER Brain Dementia PET/CT Imaging / 1 The American College of Radiology, with more than 30,000 members, is the principal organization of radiologists, radiation oncologists, and clinical medical physicists in the United States. The College is a nonprofit professional society whose primary purposes are to advance the science of radiology, improve radiologic services to the patient, study (...) in each document. Reproduction or modification of the published practice parameter and technical standard by those entities not providing these services is not authorized. 2015 (Resolution 21)* ACR–ASNR PRACTICE PARAMETER FOR BRAIN PET/CT IMAGING IN DEMENTIA PREAMBLE This document is an educational tool designed to assist practitioners in providing appropriate radiologic care for patients. Practice Parameters and Technical Standards are not inflexible rules or requirements of practice

2019 American Society of Neuroradiology

17. Effects of a modified mindfulness-based cognitive therapy for family caregivers of people with dementia: A pilot randomized controlled trial

Effects of a modified mindfulness-based cognitive therapy for family caregivers of people with dementia: A pilot randomized controlled trial Caregivers of people with dementia experience high stress levels. Mindfulness-based cognitive therapy has been found to be effective in reducing stress and improving the psychological well-being of several populations.To explore the feasibility and preliminary effects of a modified mindfulness-based cognitive therapy for family caregivers of people (...) with dementia.In a single-blinded, parallel-group, randomized controlled trial, 36 caregivers of people with dementia were randomized to either the intervention group, receiving the 7-session modified mindfulness-based cognitive therapy in 10 weeks; or the control group, receiving the usual family care and brief education on dementia care. The brief education sessions were similar in frequency and duration to the intervention group. Various psychological outcomes of caregivers were assessed and compared

2019 EvidenceUpdates

18. Incident Atrial Fibrillation, Dementia and the Role of Anticoagulation: A Population-Based Cohort Study

Incident Atrial Fibrillation, Dementia and the Role of Anticoagulation: A Population-Based Cohort Study  Atrial fibrillation (AF) is associated with dementia. Anticoagulation may modify this relationship, but it is unclear if this is due to stroke reduction alone. Age- and sex-matched individuals from the U.K. Clinical Practice Research Datalink (2008-2016) with and without an incident diagnosis of AF were followed for a new dementia diagnosis. We estimated adjusted hazard ratios (aHRs (...) ) for incident dementia diagnosis in the AF cohort, overall and stratified by anticoagulation status, using the matched non-AF cohorts as reference. We performed a sensitivity analysis excluding individuals with stroke/transient ischaemic attack (TIA) before the observation period. Over 193,082 person-years (mean follow-up 25.7 ± 0.1 months), 347/15,276 AF (2.3%) and 1,085/76,096 non-AF (1.4%) were newly diagnosed with dementia (aHR, 1.31, 95% confidence interval, 1.15-1.49). The AF group had more co

2019 EvidenceUpdates

19. Assessment of Reported Comparative Effectiveness and Safety of Atypical Antipsychotics in the Treatment of Behavioral and Psychological Symptoms of Dementia: A Network Meta-analysis

Assessment of Reported Comparative Effectiveness and Safety of Atypical Antipsychotics in the Treatment of Behavioral and Psychological Symptoms of Dementia: A Network Meta-analysis Atypical antipsychotics offer modest effectiveness compared with placebo but with serious safety risks, including a boxed warning for the risk of death in the treatment of behavioral and psychological symptoms of dementia (BPSD). Their comparative effectiveness and safety are not fully known.To assess the relative (...) benefits and safety of atypical antipsychotics in the treatment of BPSD shown in randomized clinical trials using network meta-analysis.PubMed/MEDLINE, Embase, PsychINFO, and Cochrane Library were searched from their inception until May 31, 2018. Key terms included dementia and atypical antipsychotics.Randomized clinical trials comparing any atypical antipsychotic with another atypical antipsychotic or with placebo were included in the analysis.Two independent reviewers used a standardized data

Full Text available with Trip Pro

2019 EvidenceUpdates

20. Physical inactivity, cardiometabolic disease, and risk of dementia: an individual-participant meta-analysis. (PubMed)

Physical inactivity, cardiometabolic disease, and risk of dementia: an individual-participant meta-analysis. To examine whether physical inactivity is a risk factor for dementia, with attention to the role of cardiometabolic disease in this association and reverse causation bias that arises from changes in physical activity in the preclinical (prodromal) phase of dementia.Meta-analysis of 19 prospective observational cohort studies.The Individual-Participant-Data Meta-analysis in Working (...) Populations Consortium, the Inter-University Consortium for Political and Social Research, and the UK Data Service, including a total of 19 of a potential 9741 studies.The search strategy was designed to retrieve individual-participant data from prospective cohort studies. Exposure was physical inactivity; primary outcomes were incident all-cause dementia and Alzheimer's disease; and the secondary outcome was incident cardiometabolic disease (that is, diabetes, coronary heart disease, and stroke). Summary

Full Text available with Trip Pro

2019 BMJ